EPZM Epizyme Inc.

-1.83  -12%
Previous Close 15.12
Open 14.92
Price To Book 3.65
Market Cap 1,207,172,444
Shares 90,833,141
Volume 2,066,883
Short Ratio
Av. Daily Volume 892,852

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 dosing commenced August 2016. Noted April 23, 2018 that all Tazemetostat trials have been placed on partial clinical hold.
Adult patients with mesothelioma characterized by BAP1 loss-of-function
NDA filing due 4Q 2019. Updated Phase 2 data June 21, 2019 noted ORR of 77% and 34%.
Follicular lymphoma
NDA filing announced May 30, 2019.
Epithelioid Sarcoma
Phase 1b enrollment complete.
Tazemetostat + Atezolizumab
Relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
Phase 1 trial to be initiated 2H 2019.
Sickle cell disease

Latest News

  1. Epizyme Announces Positive Interim Data on Lead Candidate
  2. Epizyme Reports Updated Data from Phase 2 Trial of Tazemetostat in Patients with Relapsed or Refractory Follicular Lymphoma
  3. The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs
  4. Hedge Funds Have Never Been This Bullish On Epizyme Inc (EPZM)
  5. Why Is Epizyme (EPZM) Up 10.9% Since Last Earnings Report?
  6. Epizyme Reports Updated Data from Phase 2 Trial of Tazemetostat for Epithelioid Sarcoma at 2019 ASCO Annual Meeting
  7. Epizyme's NDA for Tazemetostat Eyes Epithelioid Sarcoma Cure
  8. Ahead of cancer conference, Epizyme CEO talks first drug, Regeneron competition
  9. Epizyme Submits New Drug Application to the U.S. FDA for Tazemetostat for the Treatment of Patients with Epithelioid Sarcoma
  10. Will Epizyme to Surge Higher?
  11. Epizyme to Present at Jefferies 2019 Healthcare Conference
  12. Epizyme (EPZM) Shares Surge More Than 100% YTD: Here's Why?
  13. Epizyme Announces New Tazemetostat Clinical Data to be Presented in Oral Sessions at Multiple Upcoming Medical Meetings
  14. Epizyme (EPZM) Reports Q1 Loss, Tops Revenue Estimates
  15. Epizyme: 1Q Earnings Snapshot
  16. Epizyme Provides Business Update and Reports First Quarter 2019 Financial Results
  17. If You Had Bought Epizyme (NASDAQ:EPZM) Stock Five Years Ago, You'd Be Sitting On A 39% Loss, Today
  18. Why Is Epizyme (EPZM) Down 14.4% Since Last Earnings Report?
  19. Epizyme Announces Closing of Concurrent Public Offerings and Full Exercise of Underwriter’s Option to Purchase Additional Shares